Vantictumab, formerly labeled as OMP18R5, represents the novel targeted antibody designed with specifically target OPN receptor 18R5. Such treatment is currently studied by Amgen in anticipated uses in multiple orthopedic conditions, particularly those involving abnormal skeleton resorption. Preclinical data suggest Vantictumab is able to effective